Every material Form 8-K Design Therapeutics, Inc. has filed with the SEC since May 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Design Therapeutics reported third quarter 2026 results on November 4, 2026, with a net loss of $20.3 million, up from $17.0 million a year earlier, as research and development and general and administrative expenses both rose. The company had no revenue in the figures provided, and cash, cash equivalents and investment securities were $208.6 million at September 30, 2026, down from $219.8 million at December 31, 2025, which matters to shareholders because it shows the company funding larger losses from its cash balance.
Q3 2026 net loss was $20.3 million, or $0.32 per share, versus $17.0 million, or $0.30 per share, in Q3 2025.
R&D expenses were $16.9 million in Q3 2026 versus $14.6 million a year earlier; G&A expenses were $5.3 million versus $4.7 million.
Cash and investment securities were $208.6 million at September 30, 2026, compared with $219.8 million at December 31, 2025.
The company expects a registrational plan update for DT-216P2 in Q4 2026 and 12-week RESTORE-FA data in Q1 2027.
Design Therapeutics reported a second quarter 2026 net loss of $20.2 million, up from $19.1 million a year earlier, with no revenue reported in the filing. The company ended the quarter with $207.4 million in cash and investment securities and said it is modifying the RESTORE-FA trial after four-week data, with 12-week data expected in the first quarter of 2027.
Q2 2026 net loss was $20.2 million versus $19.1 million in Q2 2025; R&D expenses were $16.4 million and G&A expenses were $5.8 million.
Cash, cash equivalents and investment securities were $207.4 million at June 30, 2026, down from $219.8 million at December 31, 2025.
Data from the DT-168 Phase 2 trial in Fuchs endothelial corneal dystrophy is now expected in 2027 due to a delay in drug supply.
Dosing began in the DT-818 Phase 1 trial in myotonic dystrophy type 1; data are expected in 2027.
Design Therapeutics reported biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich ataxia patients, including mean improvements at the 1 mpk dose on two rating scales and increases in frataxin levels. The company said the data are preliminary and that it intends to pursue a registrational path, with an update on its plans expected in the fourth quarter of 2026.
As of May 17, 2026, 16 patients had completed four weeks of weekly IV DT-216P2 across 0.1, 0.3, 0.6 and 1 mpk cohorts (n=4 per cohort).
At 1 mpk, mean improvements from baseline were 6.4 points on the modified Friedreich's Ataxia Rating Scale and 2.7 points on the Upright Stability Score.
Whole blood FXN mRNA increased 65% from baseline after four weeks at 1 mpk (p < 0.001).
No serious adverse events or treatment discontinuations were reported; three patients had mild to moderate, asymptomatic ALT elevations.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Design Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →